Analytical Data
-
基因名
SIRP alpha/CD172a
- Application
-
种属
Human
-
表达系统
HEK293
-
标签
C-Llama Fc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P78324
-
表达区间
E31-R370
-
分子量
80-90 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SIRPα (Signal Regulatory Protein Alpha), also known as CD172a, is a crucial immune checkpoint receptor predominantly expressed on myeloid cells, including macrophages and dendritic cells. It plays a significant role in modulating immune responses by interacting with CD47, a "don't eat me" signal expressed on many healthy cells, thereby inhibiting phagocytosis. The SIRPα/CD47 axis is a critical regulatory pathway in tumor immune evasion, making it an attractive target for cancer immunotherapy. Researchers have identified that blocking this interaction can enhance the phagocytosis of tumor cells by macrophages, thereby promoting anti-tumor immunity. The development of recombinant SIRPα/CD172a proteins facilitates the study of this pathway, allowing for a better understanding of its biological functions and potential therapeutic applications. Investigating SIRPα in detail also reveals its implications in various physiological and pathological processes, including autoimmunity and graft rejection. Thus, recombinant SIRPα/CD172a proteins are pivotal in exploring targeted therapies to overcome immune tolerance in cancer and other diseases, offering promising avenues for enhancing the efficacy of existing treatments and developing novel immunotherapeutic strategies.
